ImmunoGen, Inc. Announces Webcast of Presentation at the 33rd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass.--()--ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius, President and CEO, will present at the upcoming 33rd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for 9:00 am PT (12:00 pm ET) on January 13, 2015.

A webcast of this presentation will be accessible live through the "Investor Information" section of the Company's website, www.immunogen.com; a replay of the presentation will be available at the same location for two weeks.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells; the Company has also developed antibodies with anticancer activity of their own. The first product with ImmunoGen’s ADC technology is Roche’s Kadcyla®. ImmunoGen has three wholly owned product candidates in clinical testing with additional compounds in clinical testing through the Company’s partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More information about ImmunoGen can be found at www.immunogen.com.

Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.

Contacts

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
info@immunogen.com
or
For Media:
Pure Communications, Inc.
Dan Budwick, 973-271-6085

Recent Stories

RSS feed for ImmunoGen, Inc.

ImmunoGen, Inc.